On January 29, 2025, Inhibikase Therapeutics, Inc. (the “Company”) reported results from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease.
| | • | | The 201 Trial enrolled 126 people with untreated Parkinson’s disease who were, on average, 14 months from diagnosis and were dosed in equal proportions at 50 mg, 100 mg, 200 mg or placebo for 12 weeks. The primary endpoints of this trial were safety and tolerability and there were 15 secondary endpoints to evaluate treatment benefit. |
| | • | | The 201 Trial met its primary endpoint of safety and tolerability, with 95% of enrolled participants completing 12 weeks on risvodetinib. Risvodetinib adverse event observations were comparable to placebo in frequency and severity. There were no treatment-related severe adverse events. |
| | • | | In the hierarchy of 15 secondary functional assessments, risvodetinib treatment did not demonstrate an improvement in the top hierarchical efficacy measure, which was the sum of Parts 2 and 3 of the Movement Disorder Society Universal Parkinson’s Disease Rating Scale (“MDS-UPDRS”) at any dose group (50mg, 100mg or 200mg) versus placebo. |
| | • | | Risvodetinib demonstrated an improvement at 100 mg in Part 2 of the MDS-UPDRS of -1.41 points (nominal p=0.036, 95% CI (-2.27, -0.096)), and at 50 mg in the Schwab & England Activities of Daily Life Scale of +4% (nominal p=0.0004, 95% CI (+1.3%, +6.7%)). |
| | • | | Analysis of alpha-synuclein pathology using skin biopsy suggests a treatment dependent reduction in neuronal alpha-synuclein deposition in cutaneous nerve fibers across all doses. |
| | • | | Data will be presented at a future medical meeting. |
The Company will pause further development of risvodetinib as it focuses its resources on advancing lead program IkT-001Pro in pulmonary arterial hypertension (“PAH”) and will consider its strategic options for the risvodetinib program.
Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “expect,” “will,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions, including its ability to consider and identify strategic options for the risvodetinib program. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the Company’s ability to commence and execute a Phase 2b ‘702’ trial to evaluate IkT-001Pro as a treatment for PAH, as well as those risks discussed in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.
